75705-24-7

Upstream product

• 99-76-3 methyl 4-hydroxylbenzoate 
• 74950-95-1 4-(Methoxycarbonyl)phenyl 2,3,4,6-tetra-O-acetyl-β-D-glucopyranoside 
• 6919-96-6 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl bromide 
• 604-69-3 β-D-glucose pentaacetate 
• 186581-53-3 diazomethane 
• 15397-25-8 4-(β-D-glucopyranosyloxy)hydroxybenzoic acid 

Downstream Products

• 50-99-7 D-glucose 
• 99-96-7 4-hydroxy-benzoic acid 
• 1258941-37-5 allyl 4-(2',3',4'-tri-O-benzyl-β-D-glucopyranosyloxy)benzoate 
• 1258941-36-4 4-(2',3',4'-tri-O-benzyl-β-D-glucopyranosyloxy)benzoic acid 
• 1293384-58-3 4-(2',3',4'-tri-O-benzyl-6'-O-trityl-β-D-glucopyranosyloxy)benzoic acid 
• 1293384-57-2 methyl 4-(2',3',4'-tri-O-benzyl-6'-O-trityl-β-D-glucopyranosyloxy)benzoate 

Relevant academic research and scientific papers

Hydrogen-Bonding-Regulated Supramolecular Nanostructures and Impact on Multivalent Binding

Herein we describe the H-bonding-regulated nanostructure, thermodynamics, and multivalent binding of two bolaamphiphiles NDI-1 and NDI-2 consisting of a hydrophobic naphthalene diimide connected to a hydrophilic wedge by a H-bonding group and a glucose mo

PHENOL GLYCOSIDES AND THEIR USE IN THE TREATMENT OF UROLITHIASIS

The present invention relates to novel derivatives of polyphenol glycoside or polyalcohols of formula (1), wherein R1, R2, R3 is selected from the group consisting of H, OH, C(O)R4, C(0) OR4, 0 (Gly H3)n, wherein n = 0 1, 2, 3, and R4 is selected from the group consisting of H, alkyl, and Gly is a mono- or disaccharide residue. The present invention also relates to novel derivatives of glycoside polyphenols or polyalcohols, as pharmaceutical composition comprising a novel polyphenol glycoside or polyalcohols and the use of novel polyphenol glycoside or polyalcohols for the treatment of urolithiasis.

Synthesis and anti-tumor activity of glycosyl oxadiazoles derivatives

A new series of glycosyl oxadiazoles compounds were synthesized and characterized through 1H NMR, 13C NMR, IR and HRMS. The anti-tumor activities for MDA-MB-231 of all these new compounds were screened in vitro by MTT assay. Due to the modification of gastrodin analogues, the anti-tumor activities of these 1,3,4-oxadiazoles derivatives were greatly improved. Six compounds (6c, 6d, 6i, 6j, 6k and 6l) displayed relatively higher MDA-MB-231 potency with IC50 values (0.89, 0.26, 1.35, 3.60, 0.95 and 1.08 μM) compared with the reference medicine Rosiglitazone (5.23 μM).